• September 1 (THU)
  • September 2 (FRI)

Satellite Symposium 1
ASCO

New era of NSCLC EGFR mutation treatment_Updated overall survival analysis: 3G EGFR TKI Lazertinib
Date & Time Sep. 1 (Thu), 9:00-9:40 Venue Room D
Chair
  • Myung-Ju Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. Lazertinib, a new game-changer in EGFR-mutant NSCLC
    Ji-Youn Han (National Cancer Center, Korea)

Satellite Symposium 2
ASCO

Efficacy and safety of Gavreto for RET+ patients
Date & Time Sep. 1 (Thu), 9:50-10:30 Venue Room D
Chair
  • Byoung Yong Shim (The Catholic University of Korea St. Vincent’s Hospital, Korea)
Presentation
Detail
  1. The welcome rain, Gavreto: New hope for RET+ patients
    Dae Ho Lee (Asan Medical Center, Korea)

Satellite Symposium 3
ASCO

What is the roles of Lonsurf (FTD/TPI) for the treatment of CRC/GC patients?
Date & Time Sep. 1 (Thu), 12:40-13:20 Venue Room C
Chair
  • Hei-Cheul Jeung (Gangnam Severance Hospital, Korea)
Presentation
Detail
  1. 1.The role of FTD/TPI in treatment of patients with mCRC
    Ji Hyung Hong (The Catholic University of Korea Eunpyeong St. Mary's Hospital, Korea)
  2. 2.The role of FTD/TPI in treatment of patients with mGC
    Hyung-Don Kim (Asan Medical Center, Korea)

Satellite Symposium 4
ASCO

Delving deeper into the 1st & 2nd line setting CDK4/6 inhibitor data (abemaciclib) for patients with HR+ HER2- metastatic breast cancer
Date & Time Sep. 1 (Thu), 12:40-13:20 Venue Room D
Chairs
  • Sung-Bae Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. Delving deeper into the 1st & 2nd line setting CDK4/6 inhibitor data (abemaciclib) for patients with HR+ HER2- metastatic breast cancer
    Antonio Llombart (Hospital Arnau Vilanova, Spain)

Satellite Symposium 5
ASCO

Treatment strategy for uHCC patients: What can we expect from TKIs in uHCC treatment?
Date & Time Sep. 1 (Thu), 13:30-14:10 Venue Room C
Chair
  • Baek-Yeol Ryoo (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.The current role of Lenvatinib in Japanese clinical practice
    Masayuki Kurosaki (Musashino Red Cross Hospital, Japan)
  2. 2.What can we expect from TKIs in uHCC treatment?
    Jaekyung Cheon (Cha Bundang Medical Center, Korea)

Satellite Symposium 6
ASCO

Palbociclib as first in class CDK4/6 inhibitor: Milestones since 2015 FDA approval
Date & Time Sep. 1 (Thu), 13:30-14:10 Venue Room D
Chairs
  • Eun Kyung Cho (Gachon University Gil Medical Center, Korea)
Presentation
Detail
  1. Overall survival with Palbociclib: First in class CDK4/6 inhibitor in HR+ HER2- mBC
    Hee Kyung Ahn (Gachon University Gil Medical Center, Korea)

Satellite Symposium 7
ASCO

Integrating novel agents into the treatment paradigm for advanced urothelial carcinoma
Date & Time Sep. 1 (Thu), 15:50-16:30 Venue Room D
Chair
  • Sang Joon Shin (Yonsei Cancer Center, Korea)
Presentation
Detail
  1. Integrating novel agents into the treatment paradigm for la/mUC: current and future perspective
    Yoon Ji Choi (Korea University Anam Hospital, Korea)

Satellite Symposium 8
ASCO

Perspective change for first line treatment strategy in advanced renal cell carcinoma
Date & Time Sep. 1 (Thu), 16:40-17:20 Venue Room D
Chair
  • Se Hoon Park (Samsung Medical Center, Korea)
Presentation
Detail
  1. Clinical Benefits of 1L aRCC patient with two-year follow-up in CheckMate9ER
    Inkeun Park (Asan Medical Center, Korea)

Satellite Symposium 9
ASCO

Looking beneath the surface of HR+HER2- aBC
Date & Time Sep. 2 (Fri), 8:00-8:40 Venue Room B
Chair
  • Kyung Hae Jung (Asan Medical Center University of Ulsan College of Medicine, Korea)
Presentation
Detail
  1. Looking beneath the surface of HR+HER2- Abc
    Dejan Juric (Massachusetts General Hospital, USA)

Satellite Symposium 10
ASCO

Navigating the maze of cancer therapies with the answers in your hands
Date & Time Sep. 2 (Fri), 8:00-8:40 Venue Room C
Chair
  • Young Joo Min (Ulsan University Hospital, Korea)
Presentation
Detail
  1. 1.Oncology deep dive: The role of chemotherapy in the era of cancer immunotherapy
    Keun-Wook Lee (Seoul National University College of Medicine / Seoul National University Bundang Hospital)
  2. 2.Translating idea to practice and beyond: how should CRC be managed in 2022?
    Han Sang Kim (Yonsei Cancer Center, Korea)

Satellite Symposium 11
ASCO

Antiemetic usage today: Risk-adapted approach
Date & Time Sep. 2 (Fri), 8:00-8:40 Venue Room D
Chairs
  • Seong-Hoon Shin (Kosin University GospelHospital, Korea)
Presentation
Detail
  1. Antiemetic usage today: Risk-adapted approach
    Hyewon Ryu (Chungnam National University Hospital, Korea)

Satellite Symposium 12
ASCO

The evolving treatment landscape with IO based combinations in 1L GC and 1L RCC treatmen
Date & Time Sep. 2 (Fri), 10:00-10:40 treatment Room D
Chair
  • Woo Kyun Bae (Chonnam National University Hwasun Hospital, Korea)
Presentation
Detail
  1. 1.Recently updated data of OPDIVO+Cx, a new treatment for GC 1L approved over the past decade
    Jin Won Kim (Seoul National University Bundang Hospital, Korea)
  2. 2.A paradigm-changing IO DUO, 1L NIVO+IPI for mRCC: Recent updates of clinical data and real-world experiences
    Ji Hyun Park (Konkuk University Medical Center, Korea)

Satellite Symposium 13
ASCO

Transforming treatment in urothelial cancer with first-line maintenance treatment with Bavencio (Avelumab)
Date & Time Sep. 2 (Fri), 10:50-11:30 Venue Room D
Chair
  • Hyo Jin Lee (Chungnam National University Hospital, Korea)
Presentation
Detail
  1. Transforming treatment in urothelial cancer with first-line maintenance treatment with Bavencio (Avelumab)
    In-Ho Kim (Catholic University Seoul St. Mary Hospital, Korea)

Satellite Symposium 14
ASCO

1L treatment for ALK+NSCLC: How do we decide?
Date & Time Sep. 2 (Fri), 12:40-13:20 Venue Room D
Chair
  • Jin Seok Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. 1L treatment for ALK+NSCLC: How do we decide?
    Te-Chun Hsia (China Medical University Hospital, Taiwan)

Satellite Symposium 15
ASCO

Strategic approach for early stage EGFRm NSCLC patient
Date & Time Sep. 2 (Fri), 13:20-14:00 Venue Room D
Chairs
  • Ki Hyeong LEE (Chungbuk National University Hospital, Korea)
Presentation
Detail
  1. Strategic approach for early stage EGFRm NSCLC patient
    Min Hee Hong (Yonsei Cancer Center, Korea)

Satellite Symposium 16
ASCO

Enabling precision medicine with comprehensive genomic profiling
Date & Time Sep. 2 (Fri), 16:40-17:20 Venue Room D
Chair
  • Tae-You Kim (Seoul National University Hospital, Korea)
Presentation
Detail
  1. 1.Precision medicine in oncology – Today and the future
    Damon Hostin (Illumina, USA)
  2. 2.The basecamp of cancer precision medicine: Comprehensive genomic profiling
    Yeul Hong Kim (Korea University College of Medicine, Korea)